Protalix BioTherapeutics (PLX) Interest Coverage Ratio (2011 - 2025)
Protalix BioTherapeutics (PLX) posted quarterly Interest Coverage Ratio of 3.48 for Q4 2025, down 75.32% year-over-year from 14.11 in Q4 2024, and down 25.34% quarter-over-quarter from 4.66 in Q3 2025.
Protalix BioTherapeutics (PLX) Interest Coverage Ratio (2011 - 2025) Analysis & Trends
Protalix BioTherapeutics' Interest Coverage Ratio history runs 15 years deep, the most recent figure standing at 3.48 for Q4 2025.
- In Q4 2025, Interest Coverage Ratio fell 75.32% year-over-year to 3.48; the TTM figure through Mar 2026 stood at 22.46 (down 735.39% YoY), while the FY2025 annual figure was 0.11, down 241.25% from the prior year.
- Interest Coverage Ratio for Q4 2025 stood at 3.48, down from 4.66 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 5615.0 in Q4 2023, with the low at 690.83 in Q1 2025.
- The 5-year median for Interest Coverage Ratio is 2.0 (2023), against an average of 273.57.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio jumped 335.57% in 2024, then plunged 10797.41% in 2025.
- Protalix BioTherapeutics' Interest Coverage Ratio stood at 6.28 in 2021, then gained by 22.18% to 4.89 in 2022, then soared by 114915.52% to 5615.0 in 2023, then slumped by 99.75% to 14.11 in 2024, then slumped by 75.32% to 3.48 in 2025.
- Business Quant data shows PLX's Interest Coverage Ratio at 3.48 in Q4 2025, 4.66 in Q3 2025, and 690.83 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.42 |
| 10 | Protalix BioTherapeutics | 188.77 Mn | 148.11 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.48 |
| Sep 30, 2025 | 4.66 |
| Mar 31, 2025 | -690.83 |
| Dec 31, 2024 | 14.11 |
| Sep 30, 2024 | 9.66 |
| Jun 30, 2024 | -6.40 |
| Mar 31, 2024 | -6.34 |
| Dec 31, 2023 | 5,615.00 |
| Sep 30, 2023 | -4.10 |
| Jun 30, 2023 | 15.65 |
| Mar 31, 2023 | -2.28 |
| Sep 30, 2022 | -4.89 |
| Jun 30, 2022 | -8.87 |
| Mar 31, 2022 | -1.67 |
| Dec 31, 2021 | -6.28 |
| Sep 30, 2021 | -0.78 |
| Jun 30, 2021 | -4.16 |
| Mar 31, 2021 | -1.72 |
| Dec 31, 2020 | 1.31 |
| Sep 30, 2020 | -1.31 |